Clinical efficacy of puerarin injection combined with reduced glutathione in treatment of diabetic nephropathy / 重庆医学

ABSTRACT

Objective To observe the clinical effects of puerarin injection combined with reduced glutathione in the treatment of stage Ⅲ of diabetic nephropathy.Methods One hundred inpatients with stage Ⅲ of diabetic nephropathy in the Chongqing Municipal Hospital of Traditional Chinese Medicine from January 2015 to October 2016 were selected and divided into the observation group and control group according to the random number table method,50 cases in each group.Both groups took the basic therapy of controlling blood sugar,blood lipids and blood pressure.On the basis of general treatment,the control group was added with reduced glutathione injection 1.8 g/d,while on the basis of the control treatment,the observation group was added with puerarin injection 300 mg/d.Both groups were treated for 4 weeks.Fasting plasma glucose (FPG),2 h postprandial plasma glucose (2 h PG),blood pressure,blood fat,serum creatinine(SCr),blood urea nitrogen (BUN),24 h urinary total protein,urine albumin,urine β2 micro-globulin (β2-MG),NAG,and other indicators before and after treatment were detected in the two groups.Results FPG,2 h PG,blood pressure and blood fat after treatment in the observation group and control group were improved,but the improvement in the observation group was better than that in the control group (P＜0.05);the levels of SCr,BUN,24 h urine protein,urine albumin and β2 micro-globulin and urine NAG in the observation group and control group patients were reduced to some extent(P＜ 0.05),which were significantly improved compared with before treatment (P＜0.05),but the improvement degree in the observation group were better than that in the control group (P＜0.05).Conclusion Puerarin injection combined with reduced glutathione injection has obvious therapeutic effect in treating the stageⅢ of diabetic nephropathy,and has less adverse reactions,is safe and effective and can be promoted and applied in clinic.